NATIONAL INSTITUTES OF HEALTH has floated a tender for Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed). The project location is USA and the tender is closing on 29 Sep 2020. The tender notice number is RFA-CA-20-019, while the TOT Ref Number is 38612140. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.

Expired Tender

Procurement Summary

Country : USA

Summary : Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed)

Deadline : 29 Sep 2020

Other Information

Notice Type : Tender

TOT Ref.No.: 38612140

Document Ref. No. : RFA-CA-20-019

Competition : ICB

Financier : Self Financed

Purchaser Ownership : -

Tender Value : Refer Document

Purchaser's Detail

Purchaser : NATIONAL INSTITUTES OF HEALTH
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
USA
Email :FBOWebmaster@OD.NIH.GOV

Tender Details

Tender are invited for Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed)

CFDA Number : 93.394 -- Cancer Detection and Diagnosis Research

Cost Sharing or Matching Requirement : No

Estimated Total Program Funding : $1, 000, 000

Closing Date for Applications: Sep 29, 2020

Posted Date : Dec 04, 2019

Description: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Documents

 Tender Notice